에 대한 최신 뉴스 Novavax (NASDAQ:NVAX) 주식

Novavax

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

Equities

News

Health Care

Markets

IDNA

MRNA

NVAX

미국 질병통제예방센터(CDC)가 세계보건기구(WHO)와의 협력을 중단한 것으로 알려지면서 전 세계 보건 우려가 월요일 높아지는 가운데, 캘리포니아에서 희귀한 H5N9 조류 독감 변종이 발견되어 백신 회의론자 로버트 F. 케네디 주니어에 대한 상원 인준 청문회가 예정된 것과 동시에 이루어졌다.

CDC-WHO 협력 중단 및 조류 독감으로 모더나, 화이자 상승; RFK Jr. 후보 인준 청문회 예정

AMPS

BLCO

BTBT

FYBR

LBPH

LSPD

MSGM

PDCO

SNDR

TCEHY

UBSFF

USAP

새로이 등장한 블록 치과용품 제조업체인 패터슨 컴퍼니즈(NASDAQ:PDCO)가 주주 가치를 높이기 위해 매각 또는 합병을 포함한 전략적 옵션을 모색 중이라고 목요일 발표했다. 이 회사는 거래 과정을 2분기 재무 보고서의 일환으로 공개했다.

딜 디스패치: 유비소프트는 매각 협상 중, 패터슨은 매각 탐색 중, 프로마의 레카로 인수 등

HOOD

LCID

PHUN

TSLA

수요일 주요 미국 지수들이 상승했다. 다우존스 산업평균지수가 0.8% 가까이 상승하여 43,077.70을 기록했고, S&amp;P 500 지수는 0.5% 상승하여 5,842.47을 기록했다. 나스닥 지수는 0.3% 상승하여 18,367.08로 마감했다.

수요일 주목받은 주식 5종목: 로빈후드, 노바백스, 펀웨어, 루시드 그룹 그리고 테슬라

Novavax Inc

Biotech

General

CVAC

Trump Health Sec Nominee Kennedy Says He Will Support Development Of Vaccines For Bird Flu

<a href="https://www.youtube.com/watch?v=e040JFe7bK0">https://www.youtube.com/watch?v=e040JFe7bK0</a>
&nbsp;

Trump Health Sec Nominee Kennedy Says He Will Not Pause Research On Bird Flu; Says He Will "Devote The Appropriate Resources To Preventing Pandemics" With Respect To Bird Flu

<a href="https://www.youtube.com/watch?v=e040JFe7bK0" title="https://www.youtube.com/watch?v=e040JFe7bK0">https://www.youtube.com/watch?v=e040JFe7bK0</a>

BNTX

Trump Health Sec Nominee Kennedy Appears In Front Of U.S. Senate Finance Committee For Nomination Hearing; Says He Promised Trump That If Confirmed Will Do Everything Possible To Put Health Of Americans Back On Track

WIIM

Shares of vaccine stocks are trading higher. HHS Secretary nominee Robert F. Kennedy Jr. reportedly said he is not anti-vaccine ahead of upcoming confirmation hearings.

<a href="https://www.bloomberg.com/news/articles/2025-01-28/rfk-jr-says-he-s-not-anti-vaccine-sees-critical-role-for-shots?srnd=homepage-asia" title="https://www.bloomberg.com/news/articles/2025-01-28/rfk-jr-says-he-s-not-anti-vaccine-sees-critical-role-for-shots?srnd=homepage-asia">https://www.bloomberg.com/news/articles/2025-01-28/rfk-jr-says-he-s-not-anti-vaccine-sees-critical-role-for-shots?srnd=homepage-asia</a>

"RFK Jr. Says He's Not Anti-Vaccine, Sees Critical Role for Shots" - Bloomberg News

Global health concerns escalated Monday as the U.S. Centers for Disease Control and Prevention reportedly halted collaboration with the World Health Organization, coinciding with the discovery of a rare H5N9 bird flu strain in California and upcoming Senate confirmation hearings for vaccine skeptic Robert F. Kennedy Jr.
What Happened: The developments sent ripples through healthcare stocks, with vaccine manufacturers showing mixed reactions. Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) edged up 0.58%, while Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) gained 2.95% amid heightened focus on potential bird flu preparedness.
CDC official John Nkengasong&#8216;s Sunday memo, <a href="https://apnews.com/article/cdc-who-trump-548cf18b1c409c7d22e17311ccdfe1f6">viewed</a> by The Associated Press, ordered an immediate stop to all WHO collaborations, catching health experts off guard as the U.S. faces multiple health challenges, including 13 measles outbreaks this year.
The first U.S. H5N9 outbreak, detected at a Merced County duck farm alongside the more common H5N1 strain, led to the culling of 119,000 birds, Reuters reported.
The discovery comes as egg prices nationwide hit $4.15 per dozen in December. The United States Department of Agriculture is projecting a further 20% increase this year due to ongoing bird flu impacts, according to a separate Associated Press <a href="https://apnews.com/article/egg-prices-bird-flu-poultry-inflation-9ea9934e20e3fe393abb1bb85aa31c30">report</a>.
The timing is particularly significant as Kennedy, known for his vaccine skepticism, faces Senate confirmation hearings this week for Health and Human Services Secretary. His potential appointment has already influenced market sentiment, with some vaccine stocks experiencing volatility.
&#8220;The concurrent WHO separation and emerging health threats create significant uncertainty for healthcare investors,&#8221; said Dr. Jeffrey Klausner, a University of Southern California public health expert.
See Also: <a href="https://www.benzinga.com/markets/equities/25/01/43256425/nvidia-says-deepseek-an-illustration-of-how-new-ai-models-can-be-created-while-being-export-control-compliant-amid-600-billion-market-value-plunge">Nvidia Says DeepSeek An &#8216;Illustration&#8217; Of How New AI Models Can Be Created While Being Export-Control Compliant Amid $600 Billion Market Value Plunge</a>
Why It Matters: The healthcare sector&#8217;s response reflects broader market concerns. The iShares Genomics Immunology and Healthcare ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDNA#NASDAQ">IDNA</a>) has gained 1.2% year-to-date, while <a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">major vaccine producers</a> maintain substantial government contracts for flu preparedness.
Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), GlaxoSmithKline PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), and other manufacturers secured $72 million in federal funding last October for bird flu vaccine production. Moderna separately received $176 million from BARDA for mRNA-based H5N1 vaccine development.
The CDC decision follows President Donald Trump&#8216;s executive order to withdraw from WHO, though the complete withdrawal requires congressional <a href="https://www.benzinga.com/25/01/43125408/trump-signs-order-to-withdraw-us-from-who-again-cites-funding-governance-concerns">approval and a one-year notice period</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/43256454/bitcoin-ethereum-dogecoin-recover-as-deepseek-troubles-mount-for-us-tech-stocks-analyst-suggests-btc-could-hit-fresh-highs-over-upcoming-two-weeks">Bitcoin, Ethereum, Dogecoin Recover As DeepSeek Troubles Mount For US Tech Stocks: Analyst Suggests BTC Could Hit Fresh Highs Over Upcoming Two Weeks</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Moderna, Pfizer Surge Amid CDC-WHO Split And Bird Flu; RFK Jr. Nomination Looms — A Recipe For The Perfect Storm?

As the bird flu virus continues to spread through the United States among poultry, dairy cows and several recent human cases among poultry workers, on Tuesday the Trump administration ordered all communications from the Centers for Disease Control <a href="https://www.benzinga.com/general/biotech/25/01/42854890/us-records-first-human-bird-flu-death-high-levels-of-respiratory-illnesses-vaccine-stocks-rally">and Prevention to stop</a>.&nbsp;
The Details: Acting Secretary of the U.S. Department of Health and Human Services Dorothy Fink followed by halting all reports from health agencies like the CDC, Food and Drug Administration and the National Institutes of Health on Tuesday, according to <a href="https://www.washingtonpost.com/health/2025/01/22/trump-health-communications-cdc-hhs-fda/56777086-d8e4-11ef-85a9-331436ec61e9_story.html">a report</a> from the Washington Post.&nbsp;
In a memo obtained by the Associated Press, Fink communicated that an "immediate pause" was ordered on regulations, guidance, announcements, press releases, social media posts and website posts through at least Feb. 1.&nbsp;
Read Next: <a href="https://www.benzinga.com/etfs/emerging-market-etfs/25/01/43130930/trump-looking-at-10-tariff-on-china-starting-feb-1">Trump &#8216;Looking At&#8217; 10% Tariff On China Starting Feb. 1&nbsp;</a>
The pause also includes the CDC's Morbidity and Mortality Weekly Report, a Centers for Disease Control and Prevention scientific publication on health information and recommendations.
Some medical experts are concerned that the lack of communication from key health agencies could put public health in jeopardy.&nbsp;
"Not a day goes by when CDC isn't tracking a potential threat to our health," Richard Besser, MD, former acting director of the CDC, told CNN.
"Right now they are letting us know about bird flu in cows, birds, and people … Cutting off communications from CDC puts our health at risk and prevents our doctors, nurses, and public health leaders in our communities from doing their jobs. I urge the administration to quickly lift the pause," Besser continued.
Bird Flu Update: The H5 bird flu is widespread in wild birds and is causing outbreaks in poultry and U.S. dairy cows with several recent human cases in U.S. dairy and poultry workers.
There have been 67 confirmed human cases of bird flu in the U.S. since 2024, including one death. The CDC<a href="https://www.cdc.gov/bird-flu/situation-summary/index.html"> says it is</a> &#8220;watching the situation carefully and working with states to monitor people with animal exposures.&#8221;
The New York Times<a href="https://www.nytimes.com/2025/01/23/nyregion/long-island-duck-farm-bird-flu.html"> reported</a> on Thursday that an outbreak of H5NI avian flu hit the last remaining duck farm on Long Island and all 100,000 ducks on the farm must be killed.&nbsp;
Before President Donald Trump took office last week, the CDC issued a new <a href="https://www.benzinga.com/general/biotech/25/01/43046294/bird-flu-raising-red-flags-among-health-officials-cdc-urges-faster-testing">health advisory</a> recommending that hospitalized patients who have tested positive for influenza be tested for the bird flu <a href="https://www.benzinga.com/general/biotech/25/01/42854890/us-records-first-human-bird-flu-death-high-levels-of-respiratory-illnesses-vaccine-stocks-rally">virus within 24 hours.&nbsp;</a>
Vaccines: Last Friday Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) announced<a href="https://www.benzinga.com/general/biotech/25/01/43117087/bird-flu-update-first-commercial-case-in-georgia-moderna-receives-590-million-to-develop-vaccine"> it received</a> an additional $590 million award from the HHS to accelerate the development of its mRNA-based influenza vaccines, including bird flu.
Other pharmaceutical companies, including Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), have bird flu vaccine candidates currently in clinical trials and CureVac NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) started a phase I/II study on its bird flu vaccine candidate developed in collaboration with GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>).&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/01/43106379/trump-reverses-bidens-ai-policies-on-day-1-what-it-means-for-tech-giants-nvidia-amd-alphabet">Trump Reverses Biden&#8217;s AI Policies On Day 1: What It Means For Tech Giants Nvidia, AMD, Alphabet&nbsp;</a></li>
</ul>
Photo via Shutterstock.

Government

Politics

Trump Administration Halts All Communications From The Centers For Disease Control As Bird Flu Spreads

According to the latest data from the Centers for Disease Control and Prevention, the current bird flu outbreak has caused 67 human cases of bird flu in the U.S. and one death associated with the virus. The virus was confirmed on Friday at a commercial poultry production facility in Georgia, the nation's top state <a href="https://www.benzinga.com/general/biotech/25/01/43046294/bird-flu-raising-red-flags-among-health-officials-cdc-urges-faster-testing">for chicken production. </a>
What To Know: The CDC said that the current public health risk is low and the agency is watching the situation carefully and monitoring people with animal exposures. Bird flu is "widespread in wild birds worldwide and is causing outbreaks in poultry and U.S. dairy cows with several recent human cases in U.S. dairy and poultry workers," the CDC stated in its <a href="https://www.cdc.gov/bird-flu/situation-summary/index.html">most recent</a> update.&nbsp;
On Friday, the Georgia Department of Agriculture announced it <a href="https://agr.georgia.gov/avian-influenza">detected</a> a case of Highly Pathogenic Avian Influenza at a commercial poultry producer in the state. The case marks the first in Georgia, the nation's top state for chicken production, since the 2022 countrywide outbreak. 
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/01/43106379/trump-reverses-bidens-ai-policies-on-day-1-what-it-means-for-tech-giants-nvidia-amd-alphabet">Trump Reverses Biden&#8217;s AI Policies On Day 1: What It Means For Tech Giants Nvidia, AMD, Alphabet&nbsp;</a>
"This is a serious threat to Georgia's #1 industry and the livelihoods of thousands of Georgians who make their living in our state's poultry industry," Georgia Agriculture Commissioner Tyler Harper said in a news release.&nbsp;
According to an AP News<a href="https://apnews.com/article/bird-flu-georgia-chicken-commercial-flock-a5bcad4662d4cf60212f6acb4a55d2ad"> report,</a> the bird flu virus has been detected in 84 commercial and backyard flocks in the past month with 10.7 million birds affected. The virus has also been confirmed in dozens of dairy farms.
What Else: On Friday, Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) announced <a href="https://www.benzinga.com/general/biotech/25/01/43105845/why-is-moderna-stock-trading-higher-on-tuesday-2">it received</a> an additional $590 million award from the U.S. Department of Health and Human Services (HHS) to accelerate the development of its mRNA-based influenza vaccines, including bird flu.
In 2023, Moderna commenced a Phase 1/2 study to generate safety and immunogenicity data for an investigational pandemic influenza vaccine (mRNA-1018) candidate against the H5 and H7 avian influenza viruses. Based on the preliminary data from the Phase 1/2 study, Moderna is preparing to advance mRNA-1018 into Phase 3. 
Other pharmaceutical companies, including Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), have bird flu vaccine candidates currently in clinical trials. 
CureVac BV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) started a phase I/II study on its bird flu vaccine candidate developed in collaboration with GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>). 
Egg producer Cal-Maine Foods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALM#NYSE">CALM</a>) reported<a href="https://www.benzinga.com/news/earnings/25/01/42862269/cal-maine-foods-stock-climbs-after-strong-q2-results-eps-beat-revenues-beat"> its most recent </a>quarterly revenue of $954.7 million, well above the  $751.49 million consensus estimate, due in part to restricted supply resulting from highly pathogenic avian influenza (HPAI) outbreaks. Cal-Maine Foods stock gained more than 75% over the past six months. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/initiation/25/01/43102452/roku-analyst-sees-25-upside-as-tv-ad-dollars-go-digital">Roku Analyst Sees 25% Upside As TV Ad Dollars Go Digital&nbsp;</a></li>
</ul>
Photo: Shutterstock

CALM

Bird Flu Update: First Commercial Case In Georgia, Moderna Receives $590 Million To Develop Vaccine

The CDC issued a health advisory Thursday recommending that hospitalized patients who have tested positive for influenza be tested for the bird flu <a href="https://www.benzinga.com/general/biotech/25/01/42854890/us-records-first-human-bird-flu-death-high-levels-of-respiratory-illnesses-vaccine-stocks-rally">virus within 24 hours.&nbsp;</a>
What To Know: There have been 67 confirmed human cases of bird flu in the U.S. since 2024 and the CDC<a href="https://www.cdc.gov/bird-flu/situation-summary/index.html"> says it is</a> "watching the situation carefully and working with states to monitor people with animal exposures."
The CDC's latest H5N1<a href="https://www.cdc.gov/han/2025/han00520.html"> bird flu advisory</a> comes as new cases continue to be revealed. On Wednesday, the CDC confirmed a bird flu infection in a child in the San Francisco area who was not hospitalized and has since recovered. The CDC said it is still investigating how the child was exposed to the virus. 
Read Next: <a href="https://www.benzinga.com/general/health-care/25/01/43041254/unitedhealth-ceo-highlights-hospitals-doctors-pharmas-role-in-soaring-health-care-costs">UnitedHealth CEO Highlights Hospitals, Doctors, Pharma&#8217;s Role In Soaring Health Care Costs</a>&nbsp;
According to a Washington Post<a href="https://www.washingtonpost.com/health/2025/01/16/bird-flu-testing-patients-in-hospital/"> report</a>, Nirav Shah, CDC's principal deputy director, said the latest recommendation is meant to accelerate testing rather than increase the number of tests being performed.&nbsp;
Shah said it was prompted by cases in which infected patients were later confirmed to have bird flu, including after being discharged.
Earlier this month, the Louisiana Department of Health reported the first human death in the U.S. related to the H5N1 bird flu virus.
Vaccine Makers: Shares of vaccine-related stocks are on watch as previous bird flu developments have caused shares to spike.&nbsp;
Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) received a $176 million government contract in July to advance development of its bird flu vaccine, leveraging the same mRNA technology used in the company's COVID-19 vaccine.  
Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) has a bird flu vaccine in clinical trials<a href="https://www.benzinga.com/general/biotech/24/11/41878334/fda-gives-green-signal-to-novavaxs-covid-19-influenza-combo-vaccine-late-stage-trial"> in addition</a> to a COVID-19-influenza combination vaccine in late-stage clinical trials. 
CureVac N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) stock is also on watch as the company has started a phase I/II study on its bird flu vaccine developed in collaboration with GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>).  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/43007213/experts-see-the-fed-on-hold-for-now-if-there-are-any-cuts-at-all-in-2025-after-decembers-sticky-consumer-inflation-report">Interest Rate Cuts &#8216;On Hold&#8230; If There Are Any At All In 2025&#8217; After December&#8217;s Sticky Consumer Inflation Report: Economists&nbsp;</a></li>
</ul>
Photo: Shutterstock

Bird Flu Raising Red Flags Among Health Officials, CDC Urges Faster Testing

<a href="https://www.washingtonpost.com/health/2025/01/16/bird-flu-testing-patients-in-hospital/">https://www.washingtonpost.com/health/2025/01/16/bird-flu-testing-patients-in-hospital/</a>
&nbsp;
The Centers for Disease Control and Prevention says hospitals treating people for the flu should test them for avian influenza within 24 hours.

AEMD

'As Bird Flu Affects More People And Animals, CDC Urges Faster Testing' - Washington Post

Novavax's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NYSE">NVAX</a>) short percent of float has fallen 5.74% since its last report. The company recently reported that it has 36.92 million shares sold short, which is 28.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 11.49 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Novavax Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736784016_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Novavax has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Novavax's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Novavax's peer group average for short interest as a percentage of float is 12.58%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Novavax's Recent Short Interest

Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares are trading lower by 9.8% to $8.40 during Monday&#8217;s session amid weakness in vaccine stocks after Moderna issued 2025 revenue guidance <a href="https://www.benzinga.com/25/01/42946454/moderna-expects-lower-annual-sales-expands-cost-cutting-initiatives">below analyst estimates</a>.
What To Know: Shares of several vaccine makers, including Novavax, dropped sharply on Monday as Moderna&#8217;s announcement of lower-than-expected 2025 revenue projections rattled investor confidence across the sector.
Moderna, whose stock fell around 23% Monday morning, expects 2025 revenues of $1.5 billion to $2.5 billion, significantly below the consensus of $2.95 billion, largely tied to weakening demand for its Spikevax COVID-19 vaccine and mRESVIA RSV vaccine.
Read Also: <a href="https://www.benzinga.com/news/25/01/42901509/why-novavax-nvax-stock-is-volatile-this-week">Why Novavax Stock Is Volatile This Week</a>
The news also intensified concerns about diminishing COVID-19 vaccine revenues and broader industry challenges as pandemic-driven demand continues to wane. 
What Else: Novavax, which relies heavily on its COVID-19 vaccine sales, saw its stock decline likely amid fears that heightened competition from Moderna's streamlined portfolio strategy could erode market share further.
The selloff could also reflect a broader skepticism about vaccine makers&#8217; ability to adapt to post-pandemic market realities, with investors reevaluating growth prospects and long-term demand for new and existing products in the space.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42944934/wall-street-slashes-interest-rate-cut-bets-after-jobs-data-are-hikes-back-on-the-table">Wall Street Slashes Interest Rate Cut Bets After Jobs Data: Are Hikes Back On The Table?</a>
<h2 class="wp-block-heading">Should I Sell My NVAX Stock?</h2>
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
Shares of Novavax have gained 94.47% year to date. This compares to the average annual return of -56.39%, meaning the stock has outperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity. 
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Novavax stock currently has an RSI of 58.05, indicating neutral conditions.
For analysis tools, charting data and access to exclusive stock news, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a>

Why Novavax (NVAX) Stock Is Falling

Shares of vaccine stocks are trading lower after Moderna issued 2025 revenue guidance below analyst estimates.

Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares dipped 11.2% to $9.60 during Wednesday&#8217;s session, pulling back<a href="https://www.benzinga.com/topic/novavax"> following recent strength. </a>
Shares of vaccine makers are volatile this week after the first bird flu death was reported in the U.S. Additionally, a recent CDC <a href="https://www.cdc.gov/respiratory-viruses/data/index.html#cdc_data_surveillance_section_2-weekly-national-summary">report</a> noted an increase in acute respiratory illness activity.
What To Know: As a company specializing in vaccine development, Novavax is positioned as a potential player in addressing such outbreaks, particularly given its history of <a href="https://www.benzinga.com/general/biotech/24/09/40688052/fda-approves-novavaxs-updated-covid-vaccine-targeting-currently-circulating-variants">creating vaccines</a> for infectious diseases.
Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/42897161/apples-24-year-70000-climb-since-itunes-faces-2025-test">Apple&#8217;s 24-Year 70,000% Climb Since iTunes Launch Faces 2025 Test</a>
While <a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">traditional bird flu vaccines</a> from Sanofi, CSL Seqirus and GlaxoSmithKline are already stockpiled, they target older H5N1 strains, leaving potential room for innovation and updates.
Novavax, with its proprietary recombinant nanoparticle vaccine technology, could be seen as a contender to develop a next-generation bird flu vaccine if demand grows. The bird flu outbreak, which has <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42471357/egg-hyperinflation-could-spike-grocery-prices-why-cal-maine-vital-farms-are-soaring">devastated poultry farms</a> and raised concerns about viral mutations, could also underscore the need for advanced vaccine platforms.
Investor speculation about potential government funding or contracts to combat the outbreak could likely contribute to volatility in Novavax shares, despite the CDC stating that <a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">public risk remains low</a>.
Read Also: <a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies</a>
<h2 class="wp-block-heading">How To Buy NVAX Stock</h2>
By now you're likely curious about how to participate in the market for Novavax &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
In the the case of Novavax, which is trading at $9.60 as of publishing time, $100 would buy you 10.41 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NVAX has a 52-week high of $23.86 and a 52-week low of $3.53.
Image courtesy of <a href="https://pixabay.com/illustrations/ai-generated-stock-exchange-bull-8477673/">Pixabay</a>

Why Novavax Stock Is Volatile This Week

The U.S. reported its <a href="https://www.benzinga.com/general/biotech/25/01/42854890/us-records-first-human-bird-flu-death-high-levels-of-respiratory-illnesses-vaccine-stocks-rally">first human death</a> from the H5 bird flu strain this week, causing a spike in vaccine developer stocks Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), CureVac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) and Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).
Vaccine production efforts are ramping up as health officials monitor the outbreak closely. In<a href="https://www.cdc.gov/bird-flu/situation-summary/index.html" target="_blank" rel="noreferrer noopener"> an update </a>on Monday, CDC said there have been 66 confirmed cases in the U.S. in the 2024 outbreak. 
CDC said the public risk remains low. Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind.
See Also: <a href="https://www.benzinga.com/news/25/01/42851023/why-novavax-nvax-stock-is-rising">Why Novavax (NVAX) Stock Is Rising</a>
<h3 class="wp-block-heading">Vaccine Providers in the Limelight</h3>
In the U.S., vaccines against H5N1 are already stockpiled. Approved shots include those from Sanofi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), CSL Seqirus, and ID Biomedical Corporation of Quebec, a subsidiary of GlaxoSmithKline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), which collectively secured $72 million in funding from the U.S. health department in October to boost the production of bird flu vaccines. These traditional vaccines, developed years ago, target older H5N1 strains but are expected to offer some protection.
Moderna, backed by $176 million from the U.S. government's BARDA, is working on an updated mRNA H5N1 vaccine. Other players, including Pfizer and GSK (in collaboration with CureVac), are testing similar candidates.
<h3 class="wp-block-heading">ETFs in Focus</h3>
For investors who want to play the trend but are wary of choosing individual biotech stocks, here are three ETFs that offer diversified exposure to the biotech companies leading the vaccine efforts. With a mix of traditional and mRNA vaccine developers in focus, these funds could benefit as the world prepares for a potential bird flu pandemic.
iShares Genomics Immunology and Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDNA#NYSE">IDNA</a>) tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index, and has already gained 2.5% so far this year. The fund has an expense ratio of 0.47%, and $129.97 million in assets under management (AUM). The fund has currently invested 4.48% of its assets in Moderna. Sanofi, GSK and Novavax are also part of its portfolio of 51 equity holdings.
First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>) derives its investment strategy from the Nasdaq US Benchmark Index, and has an expense ratio of 0.60%. Pfizer is one of its top holdings, with 7.28% of assets allocated to it.
SPDR S&amp;P Biotech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XBI#NYSE">XBI</a>) mirrors the S&amp;P&nbsp;Biotechnology Select Industry&nbsp;Index, and charges a 0.35% expense ratio. Out of its present AUM of $6.37 billion, Moderna holds 2.58%. Almost 100% of its holdings are exposed to the biotechnology sector, with only about 0.04% invested in the pharmaceutical sector.
<h3 class="wp-block-heading">The Bird Flu Menace </h3>
The bird flu scare in humans ratcheted higher in late 2024 when a 13-year-old girl in Canada fell critically ill with H5N1 and required a ventilator. Around the same time, the U.S. reported its first severe case in an elderly patient in Louisiana.
Health experts warn that vigilance is key to preventing mutations that could trigger a pandemic. While the technology to develop vaccines quickly is available, governments may need to fund large-scale clinical trials in advance to ensure rapid distribution in case of a health emergency.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42878295/quantum-stocks-tumble-why-rigetti-ionq-and-d-wave-are-falling">Quantum Stocks Tumble: Why Rigetti, IonQ and D-Wave Are Falling</a></li>
</ul>
Photo: Shutterstock.

Sector ETFs

ETFs

FTXH

Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies

The Louisiana Department of Health on Monday reported the first human death in the U.S. related to the H5N1 bird flu virus. The CDC is also reporting high levels of acute <a href="https://www.benzinga.com/news/25/01/42851023/why-novavax-nvax-stock-is-rising">respiratory illnesses nationwide</a>.&nbsp;
The Details: The Louisiana Department of Health said <a href="https://ldh.la.gov/news/H5N1-death">the patient</a>, who was over the age of 65 and had underlying health conditions, had been hospitalized since December after contracting the virus following &nbsp;exposure to a backyard flock and wild birds.&nbsp;
The CDC released<a href="https://www.cdc.gov/bird-flu/situation-summary/index.html"> an update </a>on the bird flu situation on Monday that said there have been 66 confirmed cases in the U.S. in the 2024 outbreak. The agency is monitoring for H5 bird flu activity in people and said the public health risk remains low at this time.&nbsp;
Read Next: <a href="https://www.benzinga.com/25/01/42821300/biden-set-to-ban-future-offshore-oil-drilling-4-stocks-to-watch">Biden Set To Ban Future Offshore Oil Drilling: 4 Stocks, 2 ETFs To Watch</a>
Additionally, other acute respiratory illnesses including COVID-19, influenza and RSV are at high levels and are increasing nationwide, according to the CDC's respiratory illness <a href="https://www.cdc.gov/respiratory-viruses/data/index.html">data channel</a>.&nbsp;
Vaccine Makers: Shares of vaccine-related stocks are trading higher following the latest bird flu developments, as well as the rise in acute respiratory illnesses.&nbsp;
Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) manufactures an FDA-approved COVID-19 vaccine and its pipeline includes<a href="https://www.benzinga.com/25/01/42825231/why-moderna-mrna-stock-is-trading-higher"> combination vaccines</a> targeting COVID-19, RSV and flu. Moderna received a $176 million government contract in July to advance development of its bird flu vaccine, leveraging the same mRNA technology used in the company&#8217;s COVID-19 vaccine.  
Shares of Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) are also climbing. Novavax has a bird flu vaccine in clinical trials<a href="https://www.benzinga.com/general/biotech/24/11/41878334/fda-gives-green-signal-to-novavaxs-covid-19-influenza-combo-vaccine-late-stage-trial"> in addition</a> to a COVID-19-influenza combination vaccine in late-stage clinical trials. 
CureVac N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) shares rose 22% on Monday and are climbing again Tuesday. The company has started a phase I/II study on its bird flu vaccine developed in collaboration with GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>). CureVac also has an agreement with GSK to develop second-generation influenza and COVID-19 vaccines. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/25/01/42834240/kevin-oleary-joins-the-peoples-bid-for-tiktok-as-pending-ban-looms">Kevin O&#8217;Leary Joins The People&#8217;s Bid For TikTok As Pending Ban Looms</a>&nbsp;</li>
</ul>
Photo: Shutterstock.

Movers

US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally

Shares of vaccine makers are trading higher after the first bird flu death was reporting in the US. Additionally, a recent CDC report noted an increase in acute respiratory illness activity.

Shares of Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) are trading higher by 13.5% to $11.09 during Tuesday&#8217;s session following a <a href="https://www.cdc.gov/respiratory-viruses/data/index.html#cdc_data_surveillance_section_2-weekly-national-summary">CDC report</a> highlighting a sharp increase in respiratory illnesses across the U.S. The surge, attributed to higher cases of seasonal influenza, COVID-19, and RSV, has reignited interest in vaccine developers.
Additionally, the Louisiana Department of Health this week <a href="https://www.ldh.la.gov/news/H5N1-death">reported</a> the death of the first U.S. human case of H5N1, a patient over 65 with underlying conditions who contracted the virus from backyard and wild birds, with no further cases or person-to-person transmission identified. 
Heightened awareness of H5N1 risks may boost demand for avian flu vaccines and related research initiatives.
What Else: Novavax stands out for its non-mRNA approach to combating infectious diseases. The company's flagship product, Nuvaxovid, a COVID-19 vaccine, provides an alternative for individuals who cannot or prefer not to receive mRNA-based vaccines. 
Additionally, Novavax is advancing its efforts to develop combination vaccines targeting COVID-19 and influenza, which could streamline immunization efforts against multiple respiratory viruses.
The current public health landscape could underscore the relevance of Novavax&#8217;s portfolio. During the COVID-19 pandemic, the company proved its ability to scale production as a significant player in combating respiratory illnesses.
Read Also: <a href="https://www.benzinga.com/news/25/01/42821277/why-curevac-cvac-stock-is-rising">Why CureVac Stock Is Rising</a>
<h2 class="wp-block-heading">How To Buy NVAX Stock</h2>
By now you're likely curious about how to participate in the market for Novavax &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the case of Novavax, which is trading at $10.55 as of publishing time, $100 would buy you 9.48 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NVAX has a 52-week high of $23.86 and a 52-week low of $3.53.

Why Novavax (NVAX) Stock Is Rising

Shares of vaccine makers are trading higher after the first bird flu death was reporting in the US. Additionally, a recent DCD report noted an increase in acute respiratory illness activity.

<a href="https://ldh.la.gov/news/H5N1-death#:~:text=The%20Louisiana%20Department%20of%20Health,to%20have%20underlying%20medical%20conditions.">https://ldh.la.gov/news/H5N1-death#:~:text=The%20Louisiana%20Department%20of%20Health,to%20have%20underlying%20medical%20conditions.</a>
&nbsp;
<h3>Current general public health risk remains low</h3>
January 06, 2025
The Louisiana Department of Health reports the patient who had been hospitalized with the first human case of highly pathogenic avian influenza (HPAI), or H5N1, in Louisiana and the U.S. has died. The patient was over the age of 65 and was reported to have underlying medical conditions. The patient contracted H5N1 after exposure to a combination of a non-commercial backyard flock and wild birds.&nbsp;
LDH&#39;s extensive public health investigation has identified no additional H5N1 cases nor evidence of person-to-person transmission. This patient remains the only human case of H5N1 in Louisiana.&nbsp;
The Department expresses its deepest condolences to the patient&#39;s family and friends as they mourn the loss of their loved one. Due to patient confidentiality and respect for the family, this will be the final update about the patient.&nbsp;
While the current public health risk for the general public remains low, people who work with birds, poultry or cows, or have recreational exposure to them, are at higher risk.&nbsp;
The best way to protect yourself and your family from H5N1 is to avoid sources of exposure. That means avoiding direct contact with wild birds and other animals infected with or suspected to be infected with bird flu viruses.&nbsp;
Protecting yourself and others from H5N1 infection
<ul>
<li>Do not touch sick or dead animals or their droppings and do not bring sick wild animals into your home.</li>
<li>Keep your pets away from sick or dead animals and their feces.</li>
<li>Do not eat uncooked or undercooked food. Cook poultry, eggs and other animal products to the proper temperature and prevent cross-contamination between raw and cooked food.</li>
<li>Avoid uncooked food products such as unpasteurized raw milk or cheeses from animals that have a suspected or confirmed infection.</li>
<li>If you work on poultry or dairy farms, talk to your provider about getting your seasonal flu vaccination. It will not prevent infection with avian influenza viruses, but it can reduce the risk of coinfection with avian and flu viruses.</li>
<li>Report dead or sick birds or animals to the USDA toll-free at 1-866-536-7593 or the Louisiana Department of Agriculture and Forestry Diagnostic Lab at 318-927-3441.</li>
</ul>
If you have been exposed to sick or dead birds or other animals or work on a farm where avian influenza has been detected, watch for respiratory symptoms or conjunctivitis. If you develop symptoms within 10 days after exposure to sick or dead animals, tell your healthcare provider that you have been in contact with sick animals and are concerned about avian influenza. This will help them give you appropriate advice on testing and treatment. Stay home and away from others while you have symptoms.

NNVC

'LDH Reports First U.S. H5N1-Related Human Death' - Louisiana Department Of Health

Unusual total active option classes on open include: Getty Images (GETY), Nkarta (NKTX), Truist Financial (TFC), Pac Bio (PACB), Enovix (ENVX), Nov...

Unusually active option classes on open January 7th

Moderna, Novavax and other vaccine names extend gains amid COVID/flu concerns

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Puma...

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Novavax Cashes In On Its COVID Albatross -- Challenges Remain (Rating Upgrade)

Bullish option flow detected in Novavax (NVAX) with 15,743 calls trading, 1.7x expected, and implied vol increasing over 2 points to 73.97%. 1/24 w...

Novavax call volume above normal and directionally bullish

RFK Jr. reportedly softens his antivaccine stance ahead of confirmation hearing

Bullish option flow detected in Novavax (NVAX) with 5,702 calls trading, 1.1x expected, and implied vol increasing almost 10 points to 99.21%. 1/31...

Vaccine stocks in focus as RFK Jr. faces confirmation hearing

HHS Secretary nominee RFK Jr. faces contentious Senate hearing

ARCT

ATAI

CMPS

CNSP

CRMD

CRNC

CYBN

DRUG

ENVX

GETY

GHRS

HOTH

KMDA

MNMD

MTNB

NKTX

PACB

PBYI

PLUG

SLGL

SNYNF

SWTX

TDOC

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

Earnings

Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights

Novavax to Participate in Jefferies London Healthcare Conference

Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)

Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million

Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza

Contracts

Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone

Brian Rosen, Commercial Strategy Senior Executive, Appointed as Director of Capstone Companies, Inc.

CAPC

Ardelyx

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

CareDx

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Dyne Therapeutics

89bio

Geron

Galapagos NV - American Depositary Shares

Galapagos

Immunocore Holdings plc - American Depositary Shares

Immunocore Hldgs

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

MiMedx Group

MannKind

Nurix Therapeutics

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Arcus Biosciences

ARS Pharmaceuticals

Spyre Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vir Biotechnology

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Xencor

HC Wainwright & Co.

Jefferies

B. Riley Securities

JP Morgan

B of A Securities

미국 질병통제예방센터(CDC)가 세계보건기구(WHO)와의 협력을 중단한 것으로 알려지면서 전 세계 보건 우려가 월요일 높아지는 가운데, 캘리포니아에서 희귀한 H5N9 조류 독감 변종이 발견되어 백신 회의론자 로버트 F. 케네디 주니어에 대한 상원 인준 청문회가 예정된 것과 동시에 이루어졌다.
무슨 일이 있었나: 이러한 사태는 의료 관련 주식에 파장을 일으켰고, 백신 제조사들은 혼재된 반응을 보였다. 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)는 월요일 0.58% 상승했고, 화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)는 조류 인플루엔자 대비 준비 가능성에 대한 관심이 높아지면서 2.95% 상승했다.
CDC의 존 응켄가송(John Nkengasong) 공식의 일요일 메모는 <a href="https://apnews.com/article/cdc-who-trump-548cf18b1c409c7d22e17311ccdfe1f6">AP 통신</a>에 보도된 바와 같이 WHO와의 모든 협력을 즉시 중단하라는 명령을 내렸으며, 이는 미국이 올해 13건의 홍역 발병을 포함한 여러 건강 문제에 직면한 상황에서 건강 전문가들을 놀라게 했다.
첫 번째 H5N9 발생은 머시드 카운티의 한 오리 농장에서 발견되었으며, 더 일반적인 H5N1 바이러스와 함께 발견되어 119,000마리의 조류가 도살되었다고 로이터가 보도했다.
이 발견은 전국적으로 계란 가격이 12개에 4.15달러로 치솟은 12월에 발생했다. 미국 농무부는 조류 인플루엔자 영향으로 올해 계란 가격이 추가로 20% 상승할 것으로 전망하고 있다고 별도의 AP 통신 <a href="https://apnews.com/article/egg-prices-bird-flu-poultry-inflation-9ea9934e20e3fe393abb1bb85aa31c30">보도</a>했다.
타이밍은 특히 중요하다. 백신 회의론자로 알려진 케네디는 이번 주 보건복지부 장관 인준 청문회를 앞두고 있다. 그의 잠재적 임명은 이미 시장 심리에 영향을 미쳤으며, 일부 백신 주식은 변동성을 보였다.
&#8220;동시에 WHO와의 분리와 새로운 건강 위협이 발생하는 것은 의료 투자자들에게 상당한 불확실성을 야기한다&#8221;고 제프리 클라우스너(Jeffrey Klausner) 박사, 남가주대학교 공공보건 전문가가 말했다.
참고: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%97%94%EB%B9%84%EB%94%94%EC%95%84-%EB%94%A5%EC%8B%9C%ED%81%AC%EA%B0%80-%EC%88%98%EC%B6%9C-%ED%86%B5%EC%A0%9C%EB%A5%BC-%EC%A4%80%EC%88%98%ED%95%98%EB%A9%B4%EC%84%9C-%EC%83%88-ai-%EB%AA%A8%EB%8D%B8/" target="_blank" rel="noopener">엔비디아가 딥시크를 &#8216;사례&#8217;로 언급하며 새로운 AI 모델이 수출 통제 준수 하에 생성될 수 있음을 설명</a>
중요한 이유: 의료 부문의 반응은 더 넓은 시장 우려를 반영한다. iShares Genomics Immunology and Healthcare ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDNA#NASDAQ">IDNA</a>)는 올해 1.2% 상승한 반면, <a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">주요 백신 생산자들</a>는 여전히 독감 대비를 위해 정부 계약을 상당수 보유하고 있다.
사노피 SA(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), 글락소스미스클라인 PLC(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) 그리고 다른 제조사들은 작년 10월 조류 인플루엔자 백신 생산을 위한 7,200만 달러의 연방 자금을 확보했다. 모더나는 mRNA 기반 H5N1 백신 개발을 위해 미국 보건부(HHS) 산하 질병예방대응본부(ASPR) 직속 생물의학첨단연구개발국(BARDA)로부터 1억 7,600만 달러를 별도로 받았다.
CDC의 결정은 도널드 트럼프 대통령의 WHO 탈퇴 명령에 따른 것이지만, 완전한 탈퇴는 의회의 <a href="https://www.benzinga.com/25/01/43125408/trump-signs-order-to-withdraw-us-from-who-again-cites-funding-governance-concerns">승인과 1년의 통지 기간</a>이 필요하다.

다음 읽기:
<ul>
<li><a href="https://kr.benzinga.com/crypto/bitcoin/%EB%B9%84%ED%8A%B8%EC%BD%94%EC%9D%B8-%EC%9D%B4%EB%8D%94%EB%A6%AC%EC%9B%80-%EB%B0%8F-%EB%8F%84%EC%A7%80%EC%BD%94%EC%9D%B8%EC%9D%B4-%EC%86%8C%ED%8F%AD-%ED%9A%8C%EB%B3%B5-%EB%94%A5%EC%8B%9C%ED%81%AC/" target="_blank" rel="noopener">비트코인, 이더리움, 도지코인, 딥시크 문제로 미국 기술주가 어려움을 겪는 동안 회복: 분석가는 BTC가 향후 2주 동안 새로운 최고가를 기록할 수 있다고 제안</a></li>
</ul>
이미지 출처: Shutterstock
면책 조항: 이 콘텐츠는 AI 도구의 도움을 받아 부분적으로 작성되었으며, Benzinga 편집자에 의해 검토 및 게시되었습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

<h2 class="wp-block-heading">새로이 등장한 블록</h2>
치과용품 제조업체인 패터슨 컴퍼니즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>)가 주주 가치를 높이기 위해 매각 또는 합병을 포함한 전략적 옵션을 모색 중이라고 목요일 발표했다. 이 회사는 거래 과정을 <a href="https://www.benzinga.com/24/12/42342667/dental-supplies-patterson-companies-evaluates-strategic-alternatives-after-mixed-q2-earnings-amid-challenging-end-market-environment">2분기 재무 보고서</a>의 일환으로 공개했다.
<h2 class="wp-block-heading">블록의 업데이트</h2>
이지호텔(EasyHotel)이 매각될 준비를 하고 있다. 런던 및 지역 부동산(London &amp; Regional Properties)이라는 억만장자 지원 업체가 트리스탄 캐피털 파트너스(Tristan Capital Partners)가 관리하는 펀드와 경합을 벌이고 있다. <a href="https://www.bloomberg.com/news/articles/2024-11-27/billionaire-brothers-private-equity-chase-deal-for-easyhotel">블룸버그</a>에 따르면, 경매 과정은 마지막 단계에 있다.
유비소프트 엔터테인먼트 SA(OTC:<a class="ticker" href="https://www.benzinga.com/stock/UBSFF#OTC">UBSFF</a>)가 텐센트 홀딩스 ADR(OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCEHY#OTC">TCEHY</a>)과 <a href="https://kr.benzinga.com/news/usa/stocks/%EC%9C%A0%EB%B9%84%EC%86%8C%ED%94%84%ED%8A%B8-%EC%A3%BC%EC%8B%9D-%ED%85%90%EC%84%BC%ED%8A%B8-%EC%9D%B8%EC%88%98-%EB%B3%B4%EB%8F%84-%ED%9B%84-16-%EA%B8%89%EB%93%B1/" target="_blank" rel="noopener">잠재적 인수합의</a>를 논의 중이다. 로이터에 따르면, 이번 거래는 유비소프트의 창립자인 기예모(Guillemot) 가문이 회사를 비공개로 전환할 경우에도 통제권을 유지할 수 있도록 할 것이다. 이는 <a href="https://www.benzinga.com/general/gaming/24/09/40801168/ubisoft-is-mismanaged-shareholders-are-hostages-investor-demands-video-game-company-go-private-aft">우여곡절이 많았던 한 해</a>를 보낸 유비소프트에 따른 발전으로, 이는 인력 감축, 실망스러운 매출, 여러 스튜디오 폐쇄로 이어졌다. 이 인수 논의 소식이 전해진 후, 유비소프트의 주가는 14% 급등했다.
라이트스피드 커머스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSPD#NYSE">LSPD</a>)가 구조 조정을 하고 있다. 이번 구조 조정 비용의 대부분은 2025 회계연도 3분기에 발생할 것이다. &#8220;우리 사업의 복잡성을 줄이는 데 중점을 두고 있다&#8221;고 라이트스피드의 창립자이자 CEO인 댁스 다실바(Dax Dasilva)가 <a href="https://investors.lightspeedhq.com/English/newsroom/news-details/2024/Lightspeed-Commerce-Announces-Strategic-Reorganization-Continues-to-Optimize-for-Profitable-Growth/default.aspx">말했다</a>. 한 분석가는 페이먼츠 다이브(<a href="https://www.paymentsdive.com/news/lightspeed-strategic-reorganization-employee-impact/734300/">Payments Dive</a>)에 라이트스피드를 매각하기 위한 준비라고 언급했습니다. JP모건과 RBC가 이 과정을 자문하고 있다고 <a href="https://www.bloomberg.com/news/articles/2024-11-07/lightspeed-looks-for-efficiencies-as-strategic-review-continues">블룸버그</a>가 보도했다.
더 보기: <a href="https://www.benzinga.com/general/space/24/12/42376708/nasa-mission-to-land-humans-on-moon-delayed-artemis-3-now-slated-for-mid-2027">NASA의 인간 달 착륙 미션 연기 &#8211; 아르테미스 3는 이제 2027년 중반으로 예정</a>
<h2 class="wp-block-heading">블록에서 제외</h2>
노바백스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>)가 노보 노디스크 A/S(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)에 <a href="https://www.benzinga.com/pressreleases/24/12/n42308359/novavax-announces-sale-of-czech-republic-manufacturing-site-to-novo-nordisk-for-200-million" target="_blank" rel="noreferrer noopener">2억 달러에</a> 체코 보후밀 제조 시설을 매각하기로 합의했다. 이 거래에는 150,000평방피트의 공장 <a href="https://www.benzinga.com/24/12/42323263/wegovy-maker-novo-nordisk-to-buy-novavaxs-czech-republic-manufacturing-facility-for-200-million">과 기존 인력의 이전</a>이 포함된다.
슈나이더 내셔널(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>)이 코완 시스템즈(Cowan Systems, LLC)와 그 계열사들을 약 3억 9천만 달러 <a href="https://www.benzinga.com/pressreleases/24/11/b42167845/schneiders-dedicated-momentum-continues-to-build-with-latest-acquisition-of-cowan-systems-llc" target="_blank" rel="noreferrer noopener">현금으로 인수하기로 합의했다</a>고 발표했다. 이 거래에는 관련 부동산의 별도 매입도 포함되어 있으며 <a href="https://www.benzinga.com/news/mid-cap/24/11/42170700/schneider-expands-its-fleet-390-million-cowan-systems-deal-supercharges-dedicated-services">3천 1백만 달러</a>에 이루어진다.
리뉴위(Renewi), 런던에 상장된 폐기물 관리 회사가 맥쿼리 에셋 매니지먼트로부터 7억 9십만 파운드(8억 8,880만 달러)로 평가되는 인수 <a href="https://www.macquarie.com/assets/macq/about/company/macquarie-asset-management/project-earth/joint-statement-regarding-a-final-possible-cash-offer-for-renewi-by-macquarie.pdf" target="_blank" rel="noopener">제안</a>을 받았다고 공식 발표했다. 리뉴위는 부채를 줄이고 네덜란드, 벨기에, 프랑스 및 포르투갈의 핵심 재활용 사업에 집중하기 위해 특정 자산(즉, 영국 지방 부문) 매각을 검토하고 있었다.
<h2 class="wp-block-heading">파산 블록</h2>
이지스(Eegee&#8217;s), 1971년 투손에서 설립된 인기 드라이브 스루 레스토랑 체인이 챕터 11 파산을 신청하고 투손의 네 곳과 피닉스의 한 곳, 총 다섯 개의 매장을 폐쇄했다. 도전에도 불구하고 이지스는 투손과 피닉스에 20개 이상의 매장을 계속 운영하고 있다. 현지 언론 <a href="https://www.kold.com/2024/12/06/eegees-closes-five-restaurants-files-bankruptcy/">보도에 따르면</a> 회사는 상당한 부채를 안고 있으며, 시스코(Sysco)에 120만 달러 이상, 기타 공급업체에 수십만 달러를 빚지고 있어 총 부채가 1천만 달러에서 5천만 달러 사이이다. CEO 크리스 웨스트콧(Chris Westcott)는 재구성의 이유로 여러 압박을 언급했지만, 현지 주민들은 2018년부터 이지스의 소유주인 39 노스 캐피털을 비난했다.
트럭 운송 회사인 Kal Freight가 수익성이 좋지 않은 수직적 통합 비즈니스로의 전환 시도와 코로나19 팬데믹 정점기 추가 차량 투자에 대한 의문으로 재정 상태가 악화되어 파산 보호를 신청했다. 이 회사는 또한 압류 조치를 포함한 소송에 직면해 있다고 <a href="https://www.wsj.com/articles/trucker-kal-freight-files-for-bankruptcy-protection-06194094">월스트리트 저널</a>가 목요일 미국 파산 법원에 제출한 서류를 인용해 보도했다.
프로마 그룹(Proma Group)가 독일의 레카로 오토모티브 GmbH를 <a href="https://www.promagroup.com/archive/news/68" target="_blank" rel="noopener">인수함</a>으로써 회사를 파산에서 탈출시키고 2025년 1월부터 유럽 전역에서 운영을 재개할 수 있게 되었다. 레카로의 애프터마켓 시트는 1월에 다시 시장에 출시될 예정이며, OEM 생산은 프로마가 본사인 이탈리아로 이전된다. 레카로의 영업 및 기술 부서의 몇몇 직원은 원활한 전환 및 고객 지원을 보장하기 위해 슈투트가르트 지역에 남아 있다. 레카로의 북미 및 일본 운영은 영향을 받지 않는다. 프로마 그룹의 CEO인 루카 피노(Luca Pino)는 이 파트너십을 독일 산업 및 이탈리아 제조 우수성의 조합으로 칭찬했다.
<h2 class="wp-block-heading">블록의 메모</h2>
베인 앤 컴퍼니가 이번 주 M&amp;A 통신 트렌드를 잘 정리했다. 우리가 배운 것은 다음과 같다:
<ul>
<li>2023년 1~3분기 전 세계 거래 가치가 약 240억 달러에서 2024년 같은 기간 900억 달러로 &#8220;급증&#8221;했다고 이 회사가 지적했다. 미주 지역이 전 세계 총액의 63%를 차지했다.</li>
<li>재무 투자자들이 타워와 고정 자산을 인수하고 있다. 이 추세는 디지털 인프라의 비즈니스 기본 요소에 대한 신뢰를 강조하지만, 역풍이 있다.</li>
<li>프론티어 커뮤니케이션즈 패런트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FYBR#NASDAQ">FYBR</a>)와 버라이즌 커뮤니케이션스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) 간의 <a href="https://www.benzinga.com/markets/equities/24/09/40727235/verizon-to-acquire-frontier-in-20b-deal-reaffirms-fy24-outlook" target="_blank" rel="noopener">203억 달러 규모의 거래</a>가 지금까지 올해의 최대 거래이다.</li>
<li>규모 거래가 올해까지 전 세계 거래 가치의 거의 절반을 차지했으며, 인프라 매각이 2024년 1~9월 거래 가치의 22%를 차지했다(지난 5년간 모든 거래 가치의 36%); 이동통신 및 고정 매각이 약 20%를 차지했다. 전체 보고서를 보려면 <a href="https://www.bain.com/insights/telecom-m-and-a-here-are-the-latest-deal-trends-worldwide-interactive/">여기를 클릭하십시오</a>.
<div class="ticker-wrapper">
<div class="sc-icgYrN gsJcQM ticker-box-wrapper">
<div>
<div class="relative w-fit">
<div class="inline-flex relative truncate w-full"></div>
</div>
</div>
</div>
</div>
</li>
</ul>
지난주의 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%94%9C-%EB%94%94%EC%8A%A4%ED%8C%A8%EC%B9%98-%EC%8A%A4%ED%86%A8%EB%A6%AC-%EB%AF%B8%EA%B5%AD-%EC%82%AC%EC%97%85%EB%B6%80-%ED%8C%8C%EC%82%B0-%EB%B3%B4%ED%98%B8-%EC%8B%A0%EC%B2%AD-%EC%95%A8%EB%A6%AC/" target="_blank" rel="noopener">딜 디스패치에 대한 내용을 보려면 여기를 클릭하십시오</a><a href="https://www.benzinga.com/news/asset-sales/24/11/42254293/deal-dispatch-stoli-bankrupt-ally-financial-to-sell-credit-card-unit">.</a>
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42370712/bitcoins-flash-crash-is-a-classic-bull-market-shakeout-says-trader-watch-these-3-scenarios">비트코인 급락: 전형적인 강세장 시장 조정?</a></li>
</ul>
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

수요일 주요 미국 지수들이 상승했다. 다우존스 산업평균지수가 0.8% 가까이 상승하여 43,077.70을 기록했고, S&amp;P 500 지수는 0.5% 상승하여 5,842.47을 기록했다. 나스닥 지수는 0.3% 상승하여 18,367.08로 마감했다.
이날 소매 거래자들과 투자자들의 주목을 받은 주요 주식들은 다음과 같다:
로빈후드 마켓 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>)
로빈후드의 주가는 0.49% 상승하여 $26.93에 마감했다. 이 주식의 장중 고가와 저가는 각각 $27.17와 $26.57였으며, 52주 범위는 $7.91에서 $27.33이다. 이 회사의 CEO인 블래디미어 테네브(Vlad Tenev)는 플로리다 마이애미에서 열린 후드 서밋 2024(HOOD Summit 2024)에서 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%A1%9C%EB%B9%88%ED%9B%84%EB%93%9C-%EB%A7%88%EC%BC%93-%EC%84%A0%EB%AC%BC-%EA%B1%B0%EB%9E%98-%EB%B0%8F-%EC%A7%80%EC%88%98-%EC%98%B5%EC%85%98-%EA%B1%B0%EB%9E%98-%EB%B0%9C%ED%91%9C/" target="_blank" rel="noopener">선물 거래와 지수 옵션 거래의 출시</a>를 발표했다.
노바백스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>)
노바백스의 주가는 19.44% 하락하여 $10.15에 마감했다. 장중 고가와 저가는 각각 $10.67와 $9.62였으며, 52주 범위는 $3.53에서 $23.86이다. 미 식품의약청(FDA)이 노바백스의 COVID-19-인플루엔자 혼합 백신 후보에 대해 <a href="https://www.benzinga.com/general/biotech/24/10/41356844/fda-puts-speed-breaker-on-novavaxs-covidflu-combo-shot-trial-on-concerns-related-to-damaged-nerve">임상 보류</a>를 결정했다. 이는 2상 시험 참가자에게 보고된 심각한 이상 반응 때문이다.
또한 보기: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41306985/coinbase-ceo-brian-armstrong-wants-to-know-how-elon-musk-gets-so-much-done-wants-an-in-dep?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">코인베이스의 CEO 브라이언 암스트롱이 일론 머스크가 어떻게 이렇게 많은 일을 하는지 알고 싶어 함 — 심층 연구 요청</a>
펀웨어 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>)
펀웨어의 주가는 17.63% 상승하여 $6.34에 마감했다. 장중 고가와 저가는 각각 $6.62와 $5.8였으며, 52주 범위는 $2.85에서 $24.5이다. 이 회사는 <a href="https://www.benzinga.com/markets/equities/24/10/41358201/whats-going-on-with-trump-related-phunware-stock-today">AI 기반 플랫폼에 대한 투자 계획</a>을 발표했다. 이 회사는 도널드 트럼프 2020 대선 캠페인 앱의 성공적인 개발을 회상하며 옹호 및 유권자 참여를 위한 AI 기반 플랫폼에 투자할 계획을 발표했다.
루시드 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>)
루시드의 주가는 0.31% 상승하여 $3.28에 마감되었다. 장중 고가와 저가는 각각 $3.33와 $3.26였으며, 52주 범위는 $2.29에서 $5.31이다. 이 회사는 <a href="https://www.benzinga.com/news/24/10/41369986/lucid-stock-is-tumbling-wednesday-whats-driving-the-action">보통주 262,446,931주의 공모</a>를 발표했으며, 사우디 국부 펀드(PIF) 계열사의 투자도 함께 발표되었다.
테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
테슬라의 주가는 0.80% 상승하여 $221.33에 마감되었다. 장중 고가와 저가는 각각 $222.82와 $218.93였으며, 52주 범위는 $138.8에서 $271이다. 테슬라는 <a href="https://www.benzinga.com/news/24/10/41353805/elon-musks-tesla-dominates-us-ev-market-with-3-of-top-5-best-selling-models-in-q3">3분기 미국 전기차 시장</a>에서 판매량 기준으로 상위 5개 모델 중 3개를 차지하며 시장을 지배했다. 이는 켈리 블루 북(Kelley Blue Book)의 추정에 따른 것이다.
사진 출처: Shutterstock
당일 거래를 준비하려면 <a href="Premarket Movers &amp; News">Benzinga의 주요 프리마켓 움직임 및 뉴스</a>를 확인하세요.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41328454/why-nvidia-amd-and-other-chipmakers-are-moving-lower-in-tuesdays-premarket?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">엔비디아, AMD 및 기타 반도체 제조사들이 화요일 프리마켓에서 하락하는 이유</a></li>
</ul>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에 의해 생성되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>에 의해 편집되었습니다.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

매주 ‘벤징가의 스톡 위스퍼 지수(Benzinga's Stock Whisper Index)'는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 <a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">표면 바로 아래에서 주목을 끌고</a> 있는 주식 5종목을 소개한다.
투자자들은 가치가 저평가된, 관심이 적은, 새로운 주식들을 항상 찾고 있다. 소매 트레이더들에게 제공되는 무수한 방법 중에서 방대한 양의 정보를 좁혀내어 새로운 정보를 찾아내는 것이 어려운 경우가 많다. 이 지수에는 이러한 주식들이 왜 중요한지, 투자자나 일반 독자가 이 주식들을 주목해야 하는 이유에 대한 편집 논평이 포함되어 있다.
9월 6일 주의 벤징가 스톡 위스퍼 지수의 개요:
1. 오라클 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>): 이 기술 대기업은 월요일에 있을 1분기 재무 결과 발표를 앞두고 Benzinga 독자들로부터 강한 관심을 받고 있다.
이 회사는 작년 1분기의 1.19달러에서 증가한 1.33달러의 주당 순이익(EPS)을 보고할 것으로 예상된다. <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1" target="_blank" rel="noopener">Benzinga Pro</a>의 데이터에 따르면 이 회사는 7분기 연속, 그리고 지난 10분기 중 8분기 동안 분석가들의 주당 순이익 추정치를 상회했다.
분석가들은 이 회사의 1분기 매출이 작년 1분기의 129억 4천만 달러에서 증가한 132억 4천만 달러로 보고될 것으로 추정한다. 이 회사는 4분기 연속으로, 그리고 지난 10분기 중 6분기 동안 분석가들의 매출 추정치를 달성하지 못했다.
오라클은 오픈AI와의 대규모 계약을 포함해 125억 달러 이상의 가치가 있는 30개 이상의 AI 판매 계약을 체결하여 4분기에 <a href="https://www.benzinga.com/news/earnings/24/06/39280057/oracle-misses-q4-earnings-stock-surges-on-booming-ai-demand-openai-contract-partnership-with-google" target="_blank" rel="noopener" data-google-interstitial="false">AI 수요를 강조</a>했다. 오라클은 당시 구글 클라우드와의 파트너십도 발표했다.
아래 <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1" target="_blank" rel="noopener">Benzinga Pro 차트</a>에서 볼 수 있듯이 오라클의 주가는 지난 5일 동안 1.05% 상승했다. 오라클 주식은 2024년 현재까지 36.28% 상승했다. 이 주식은 금요일 0.56% 하락한 141.,81달러에 마감했다.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-534842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105358/Screenshot-162.png" sizes="(max-width: 993px) 100vw, 993px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105358/Screenshot-162.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105358/Screenshot-162-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105358/Screenshot-162-768x388.png 768w" alt="" width="993" height="502" /></a></figure>
2. 노바백스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>): 미국 식품의약국(FDA)이 회사의 <a href="https://www.benzinga.com/general/biotech/24/09/40688052/fda-approves-novavaxs-updated-covid-vaccine-targeting-currently-circulating-variants">업데이트된 COVID-19 백신</a>에 대한 긴급 사용 승인을 승인했다는 소식이 전해지면서 이 백신 회사의 주가는 지난 5일 동안 1.48% 상승했다. 이 업데이트된 백신은 미국 질병 통제 예방 센터(CDC)의 권장 사항에 포함되어 있다.
이 백신은 미국에서 12세 이상의 사람들이 COVID-19 예방을 위해 사용할 수 있는 유일한 단백질 기반 옵션이다. 이 회사는 또한 다음 주 두 번의 회사 프레젠테이션을 앞두고 투자자들의 관심을 끌 수도 있다. 노바백스는 9월 9일 월요일과 9월 10일 화요일에 각각 H.C. 웨인라이트(Wainwright)와 베어드(Baird) 투자자 컨퍼런스에 참석할 예정이다.
노바백스의 주식은 금요일 2.68% 하락한 11.63달러에 마감되었다.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-534844" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105414/Screenshot-163.png" sizes="(max-width: 989px) 100vw, 989px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105414/Screenshot-163.png 989w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105414/Screenshot-163-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105414/Screenshot-163-768x390.png 768w" alt="" width="989" height="502" /></a></figure>
읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%eb%8b%a8%eb%8f%85-2024%eb%85%84-8%ec%9b%94-%eb%b2%a4%ec%a7%95%ea%b0%80-%ed%94%84%eb%a1%9c%ec%97%90%ec%84%9c-%ea%b0%80%ec%9e%a5-%ea%b2%80%ec%83%89%eb%9f%89%ec%9d%b4-%eb%a7%8e%ec%95%98%eb%8d%98/" target="_blank" rel="noopener">독점: 2024년 8월 Benzinga Pro에서 가장 많이 검색된 20개 티커</a>
3. 휠러 리얼 에스테이트 인베스트먼트 트러스트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>): 이 부동산 투자 신탁의 주가는 회사가 순회 법원에서 시더 리얼티(Cedar Realty) 우선주 보유자들과 관련된 집단 소송 기각을 확정했다고 <a href="https://ir.whlr.us/news-events/press-releases/detail/1088/cedar-realty-trust-and-wheeler-real-estate-investment-trust-announce-fourth-circuit-court-affirms-dismissal-of-class-action-lawsuit">발표</a>한 후 주에 500% 이상 급등했다. 휠러(Wheeler)는 2022년 8월 시더(Cedar)를 인수했으며, 이번 소송은 시더의 전 이사회와 관련된 계약 위반을 주장했다.
시더와 휠러의 CEO인 앤드류 프랭클린(Andrew Franklin)은 &#8220;이 문제가 해결되었음에도 불구하고 두 회사 모두 전략 계획을 실행할 수 있는 좋은 위치를 유지하고 있다&#8221;고 말했다.
이 회사는 14개 주를 포괄하는 북동부, 중부 대서양 및 남동부 지역에 식료품점을 중심으로 한 77개의 쇼핑 센터를 소유하고 있다. 이 회사의 소송이 해결됨으로 인해 투자자들은 긍정적인 장기 전망을 볼 수 있었다.
휠러의 주식은 금요일 147.58% 급등한 10.25달러에 마감되었다. 이후 시간외 거래에서 24.88% 하락했다.
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-534845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105430/Screenshot-164.png" sizes="(max-width: 997px) 100vw, 997px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105430/Screenshot-164.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105430/Screenshot-164-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105430/Screenshot-164-768x388.png 768w" alt="" width="997" height="504" /></a>
4. 에퀴닉스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>): 이 데이터 센터 회사는 이번 주에 주가가 소폭 상승하면서 투자자들의 강한 관심을 보였다. 이 회사는 완료된 두 가지 제안에 걸쳐 7억 5천만 달러 규모의 그린 본드를 발행했다고 <a href="https://investor.equinix.com/news-events/press-releases/detail/1051/equinix-issues-more-than-750-million-in-green-bonds-to">발표</a>했다. 이 그린 본드는 회사의 지속 가능성 이니셔티브를 지원하는 데 사용된다.
&#8220;그린 본드는 자금을 확보하고 당사 운영의 지속 가능성을 향상시키는 중요한 이니셔티브를 지원하는 귀중한 수단이다&#8221;라고 에퀴닉스의 기업 금융 및 지속 가능성 SVP인 카트리나 라이밀(Katrina Rymill)이 말했다. &#8220;지난 5년 동안 우리의 그린 본드는 105개 현장에서 172개의 녹색 건물 프로젝트, 33개의 에너지 효율 프로젝트, 2개의 전력 구매 계약 프로젝트에 자금을 지원했다.&#8221;
이 새로운 그린 본드는 회사가 S&amp;P 500 기업 중 가장 긴 연속 기록인 86분기 연속 매출 성장을 지원하기 위한 새로운 노력에 계속 투자하는 데 도움이 될 수 있다.
금요일 이 회사의 주식은 0.46% 하락한 817.96달러에 마감되었다.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-534850" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105452/Screenshot-165.png" sizes="(max-width: 995px) 100vw, 995px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105452/Screenshot-165.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105452/Screenshot-165-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105452/Screenshot-165-768x387.png 768w" alt="" width="995" height="502" /></a></figure>
5. 테논 메디컬 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>): 두 가지 <a href="https://ir.tenonmed.com/">소식</a> 덕분에 이번 주 동안 이 의료기기 회사에 대한 투자자의 관심이 높아졌다. 이 회사는 9월 4일 1:8 역주식 분할을 발표했으며 이는 9월 6일부터 시행되었다. 역주식 분할은 회사의 유동 주식수와 발행 주식수를 줄이므로 소매 투자자들의 관심을 끄는 경우가 많다.
테논은 또한 카타마란 SI 관절 시스템(Catamaran SI Joint Fusion System)에 대한 종동업계 검토 간행물을 발표했다. 이 동종업계 검토 결과, 시술 후 12개월이 지난 시점에 유합의 증거가 나타났다고 회사측이 밝혔다.
이 회사의 주식은 금요일 18.82% 하락한 3.92달러에 마감되었다. 이후 시간외 거래에서 7.34% 추가 하락했다.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-534851" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105510/Screenshot-166.png" sizes="(max-width: 991px) 100vw, 991px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105510/Screenshot-166.png 991w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105510/Screenshot-166-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105510/Screenshot-166-768x389.png 768w" alt="" width="991" height="502" /></a></figure>
다음 주 보고서를 기대해 주시고, 최신 헤드라인과 <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">주요 시장 동향 뉴스를 여기서 확인하세요.</a>
최신 스톡 위스퍼 지수 보고서를 여기에서 읽어보세요:
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/08/40284758/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">8월 9일</a></li>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40420145/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">8월 16일</a></li>
<li><a href="https://www.benzinga.com/top-stories/24/08/40531771/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">8월 23일</a></li>
<li><a href="https://www.benzinga.com/exclusives/24/08/40653930/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">8월 30일</a></li>
</ul>
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40748240/how-to-earn-500-a-month-from-oracle-stock-ahead-of-q1-earnings">오라클 주식으로 월 500달러를 버는 방법</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

REIT

Stock Split

Exclusives

Tech

Real Estate

EQIX

ORCL

TNON

WHLR

벤징가의 '스톡 위스퍼' 지수: 투자자들이 몰래 주시하지만 아직 말하지 않는 주식 5종목

미국 주 중 절반 이상이 폐수에서 <a href="https://www.benzinga.com/24/07/39829417/biden-gets-covid-19-takes-a-fiesty-dig-at-tesla-ceo-im-sick-of-elon-musk-and-his-rich-buddies-trying" target="_blank" rel="noopener" data-google-interstitial="false">심각한 코비드-19(Covid-19) 활동</a>을 경험하고 있으며, 조 바이든 대통령은 수요일 자신이 세 번째로 바이러스에 감염되었다고 발표한 후 격리 상태를 유지하고 있다.
질병통제예방센터(CDC)의 최신 <a href="https://www.cdc.gov/nwss/rv/COVID19-currentlevels.html" target="_blank" rel="noopener">데이터</a>에 따르면 26개 주에서 다양한 장소에서 바이러스 수준이 &#8216;높음&#8217; 또는 &#8216;매우 높음&#8217;으로 보고되고 있다. 최고 수준의 주에는 아칸소, 캘리포니아, 플로리다, 메릴랜드, 네바다, 오리건 및 텍사스가 포함된다.
바이든 행정부는 더 이상 코비드-19를 공중 보건 비상사태로 간주하지 않고 대신 연례 예방 접종 캠페인을 통해 예방해야 하는 일상적인 호흡기 바이러스로 취급한다고 워싱턴 포스트가 <a href="https://www.washingtonpost.com/health/2024/07/18/biden-covid-summer-wave-symptoms-flirt-variant/" target="_blank" rel="noopener">보도</a>했다.
또한 읽기: <a href="https://www.benzinga.com/general/biotech/24/07/39823289/european-commission-faces-court-criticism-over-covid-vaccine-contract-transparency-ahead-of-vote-" target="_blank" rel="noopener" data-google-interstitial="false">유럽위원회, 우르줄라 폰데어라이엔의 재임명에 대한 투표를 앞두고 코로나 백신 계약 투명성에 대한 법원 비판에 직면</a>
바이든은 대통령 직무를 계속 수행하는 동안 델라웨어에 있는 자신의 레호보스 비치 자택에 머물고 있다.
주목해야 할 백신 주식: 노바백스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) 그리고 화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)는 모두 9월 말 이전에 출시될 새로운 코로나 백신을 만들고 있다고 뉴욕 타임스(New York Times)가 <a href="https://www.nytimes.com/article/long-covid-vaccine.html">보도</a>했다.
노바백스 백신은 겨울과 봄에 두드러진 변종인 JN.1을 표적으로 삼을 예정이다.
화이자와 모더나는 새로운 사례 4건 중 약 1건을 차지하는 KP.2를 겨냥한 백신을 개발하고 있다. 두 가지 관련 변종인 KP.3과 LB.1이 새로운 사례의 절반 이상을 차지하는 주범이라고 타임스가 밝혔다.
세 가지 변종 모두 JN.1의 후속이므로 각 백신이 이에 대해 효과적일 것으로 예상된다.
NVAX, MRNA, PFE 주가 동향: 목요일 노바백스 주가는 5.62% 하락한 14.96달러에 마감했다. 모더나의 주가는 2.20% 하락한 121.32달러를 기록했다. 화이의 주가는 1.07% 하락한 29.71달러에 마감했다.
백신 개발자 그룹 중 시가총액이 1,690억 달러로 가장 큰 화이자의 주식을 보유하고 있는 상장지수펀드는 목요일 오후 거래에서 하락했다.
<ul>
<li>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTHX#NASDAQ">FTHX</a>)는 1.49% 하락했다.</li>
<li>First Trust Morningstar Dividend Leaders Index Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDL#NYSE">FDL</a>)는 0.82% 하락했다.</li>
<li>Invesco Pharmceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)는 1.64% 하락했다.</li>
<li>Harbor Health Care ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEDI#NYSE">MEDI</a>) 0.88% 하락했다.</li>
<li>Invesco S &amp; P Ultra dividend Revenue ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDIV#NYSE">RDIV</a>)는 0.97% 하락했다.</li>
</ul>
사진은 셔터스톡을 통해 제공됐다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Novavax

뉴스

에 대한 최신 뉴스 Novavax (NASDAQ:NVAX) 주식

화요일, 1월 28, 2025

일요일, 12월 08, 2024

목요일, 10월 17, 2024

토요일, 9월 07, 2024

금요일, 7월 19, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌